← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

BioCryst Pharmaceuticals, Inc. (BCRX) 10-Year Financial Performance & Capital Metrics

BCRX •
HealthcareBiotechnologyCommercial Rare Disease Biopharma
AboutBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Show more
  • Revenue $875M +94.1%
  • EBITDA $341M +26390.6%
  • Net Income $264M +396.9%
  • EPS (Diluted) 1.21 +381.4%
  • Gross Margin 97.82% +0.6%
  • EBITDA Margin 38.98% +13643.2%
  • Operating Margin 38.98% +7008.4%
  • Net Margin 30.16% +252.9%
  • ROE -
  • ROIC 807.86% +110133.4%
  • Debt/Equity -
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong Piotroski F-Score: 7/9
  • ✓FCF machine: 39.7% free cash flow margin
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 117.9%
  • ✓Efficient asset utilization: 1.7x turnover

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y33.61%
5Y117.89%
3Y47.82%
TTM94.1%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM396.87%

EPS CAGR

10Y-
5Y-
3Y-
TTM378.77%

ROCE

10Y Avg-52.75%
5Y Avg-0.57%
3Y Avg26.31%
Latest105.22%

Peer Comparison

Commercial Rare Disease Biopharma
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CORTCorcept Therapeutics Incorporated3.78B35.7043.5412.79%13.01%15.3%3.75%0.01
BMRNBioMarin Pharmaceutical Inc.11.86B61.7334.2910.83%5.73%6.11%0.10
VRTXVertex Pharmaceuticals Incorporated126.19B496.8332.438.9%31.35%21.22%2.53%0.20
CPRXCatalyst Pharmaceuticals, Inc.2.83B23.0813.7419.78%36.39%22.46%7.38%0.00
HRMYHarmony Biosciences Holdings, Inc.1.65B28.5410.5321.51%18.27%18.24%21.12%0.02
PTCTPTC Therapeutics, Inc.5.45B68.198.76114.51%42.25%
BCRXBioCryst Pharmaceuticals, Inc.1.86B8.757.2394.1%30.16%18.63%
RAREUltragenyx Pharmaceutical Inc.2.26B23.39-3.7229.01%-91.95%-35.88%0.15

Compare BCRX vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs AGIO

Compare head-to-head with Agios Pharmaceuticals, Inc.

vs VRTX

Compare head-to-head with Vertex Pharmaceuticals Incorporated

Compare Top 5

vs AGIO, VRTX, ASND, BBIO

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+26.35M25.19M20.65M48.84M17.81M157.17M270.83M331.41M450.71M874.84M
Revenue Growth %-45.39%-4.43%-18%136.45%-63.53%782.38%72.31%22.37%36%94.1%
Cost of Goods Sold+2.7M1.7M471K4.1M1.68M7.26M6.59M4.66M12.48M19.07M
COGS % of Revenue10.24%6.76%2.28%8.4%9.41%4.62%2.43%1.41%2.77%2.18%
Gross Profit+23.65M23.48M20.18M44.73M16.14M149.91M264.23M326.75M438.23M855.76M
Gross Margin %89.76%93.24%97.72%91.6%90.59%95.38%97.57%98.59%97.23%97.82%
Gross Profit Growth %-48.98%-0.72%-14.06%121.65%-63.93%829.02%76.27%23.66%34.12%95.28%
Operating Expenses+72.26M80.89M114.4M144.19M190.89M327.63M412.67M430.46M440.77M514.77M
OpEx % of Revenue274.2%321.19%553.92%295.26%1071.71%208.45%152.37%129.89%97.79%58.84%
Selling, General & Admin11.25M13.93M29.51M37.12M67.93M118.82M159.37M213.89M266.13M348.65M
SG&A % of Revenue42.7%55.32%142.9%76.01%381.37%75.6%58.85%64.54%59.05%39.85%
Research & Development61.01M66.96M84.89M107.07M122.96M208.81M253.3M216.57M174.64M166.13M
R&D % of Revenue231.5%265.87%411.02%219.24%690.34%132.85%93.53%65.35%38.75%18.99%
Other Operating Expenses0000000000
Operating Income+-48.61M-57.41M-94.22M-99.45M-174.76M-177.72M-148.44M-103.71M-2.54M340.99M
Operating Margin %-184.45%-227.95%-456.2%-203.66%-981.12%-113.07%-54.81%-31.29%-0.56%38.98%
Operating Income Growth %-23.23%-18.11%-64.11%-5.56%-75.71%-1.7%16.48%30.13%97.55%13508.93%
EBITDA+-48.12M-56.71M-93.45M-98.73M-174.01M-176.94M-147M-102.05M-1.3M340.99M
EBITDA Margin %-182.61%-225.15%-452.48%-202.17%-976.92%-112.58%-54.28%-30.79%-0.29%38.98%
EBITDA Growth %-22.57%-17.84%-64.79%-5.65%-76.25%-1.69%16.92%30.57%98.73%26390.59%
D&A (Non-Cash Add-back)483K704K770K724K748K777K1.44M1.66M1.25M0
EBIT-48.66M-57.22M-92.08M-97M-168.31M-122.52M-145.29M-117.99M11.56M0
Net Interest Income+-5.69M-7.55M-6.92M-9.96M-5.08M-59.23M-93.97M-92.46M-83.77M0
Interest Income793K1.01M2.25M1.93M9.42M62K5.13M15.78M14.75M10.67M
Interest Expense6.49M8.56M9.18M11.89M14.5M59.29M99.09M108.24M98.52M-78.87M
Other Income/Expense-6.54M-8.37M-7.03M-9.44M-8.06M-4.09M-95.95M-122.52M-84.41M-73.6M
Pretax Income+-55.14M-65.78M-101.25M-108.9M-182.81M-181.81M-244.38M-226.23M-86.95M267.39M
Pretax Margin %-209.25%-261.18%-490.25%-222.99%-1026.35%-115.68%-90.24%-68.26%-19.29%30.56%
Income Tax+000002.25M2.73M310K1.93M3.53M
Effective Tax Rate %100%100%100%100%100%101.24%101.12%100.14%102.22%98.68%
Net Income+-55.14M-65.78M-101.25M-108.9M-182.81M-184.06M-247.12M-226.54M-88.88M263.86M
Net Margin %-209.25%-261.18%-490.25%-222.99%-1026.35%-117.11%-91.25%-68.36%-19.72%30.16%
Net Income Growth %-28.19%-19.29%-53.92%-7.55%-67.88%-0.68%-34.26%8.33%60.77%396.87%
Net Income (Continuing)-55.14M-65.78M-101.25M-108.9M-182.81M-184.06M-247.12M-226.54M-88.88M263.86M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.75-0.78-0.98-0.94-1.09-1.03-1.33-1.18-0.431.21
EPS Growth %-27.12%-4%-25.64%4.08%-15.96%5.5%-29.13%11.28%63.56%381.4%
EPS (Basic)-0.75-0.78-0.98-0.94-1.09-1.03-1.33-1.18-0.431.26
Diluted Shares Outstanding73.7M84.45M103.19M115.6M167.27M179.12M185.91M192.2M206.7M218.58M
Basic Shares Outstanding73.7M84.45M103.19M115.6M167.27M179.12M185.91M192.2M206.7M209.89M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+66.99M125.39M114.35M164.34M323.8M566.14M516.5M495.97M421.97M404.35M
Cash & Short-Term Investments63.58M155.69M126.84M136.23M300.37M507.6M424.31M388.99M321.06M274.75M
Cash Only22.1M50.28M26.73M114.17M272.13M504.39M304.77M110.64M104.92M89.74M
Short-Term Investments32.55M64.11M77.74M22.05M28.24M3.21M119.54M278.34M216.14M185.01M
Accounts Receivable8.77M6.12M4.29M22.15M8.65M29.41M50.6M56.95M79.07M0
Days Sales Outstanding121.4488.6575.87165.52177.1768.3168.1962.7264.03-
Inventory500K-37.8M1.65M07.04M15.79M27.53M28.68M8.09M5.4M
Days Inventory Outstanding67.62-1.28K-1.53K793.461.52K2.25K236.42103.29
Other Current Assets1.63M3.5M1.54M1.55M2.22M3.35M14.06M21.35M13.75M124.2M
Total Non-Current Assets+22.86M52.87M32.49M10.94M10.91M22.02M33.5M20.99M68.45M109.81M
Property, Plant & Equipment9.92M9.55M9.13M7.35M7.11M15.19M8.62M20.91M19.79M18.99M
Fixed Asset Turnover2.66x2.64x2.26x6.65x2.50x10.35x31.43x15.85x22.78x46.08x
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments8.93M41.3M22.38M006.83M18.08M021.72M61.16M
Other Non-Current Assets4.01M2.03M978K3.59M3.8M06.81M80K26.94M29.66M
Total Assets+89.85M178.26M146.84M175.28M334.71M588.15M550M516.96M490.42M514.16M
Asset Turnover0.29x0.14x0.14x0.28x0.05x0.27x0.49x0.64x0.92x1.70x
Asset Growth %-27.87%98.4%-17.62%19.37%90.96%75.72%-6.49%-6.01%-5.13%4.84%
Total Current Liabilities+54.36M74.84M69.48M92.33M105.65M103.72M105.51M149.99M160.38M196.07M
Accounts Payable4.27M6.34M7.77M13.99M18.71M27.81M14.36M20.89M11.64M15.83M
Days Payables Outstanding577.321.36K6.02K1.24K4.08K1.4K794.651.64K340.41302.83
Short-Term Debt28.24M35.15M33.7M38.58M30M00035.45M1.63M
Deferred Revenue (Current)2.02M8.48M221K2.12M150K1.42M1.22M000
Other Current Liabilities19.4M21.89M23.08M6.19M44.58M52M36.46M86.59M64.66M194.44M
Current Ratio1.23x1.68x1.65x1.78x3.06x5.46x4.90x3.31x2.63x2.06x
Quick Ratio1.22x2.18x1.62x1.78x3.00x5.31x4.63x3.12x2.58x2.03x
Cash Conversion Cycle-388.26--4.67K--2.37K-535.52797.58672.75-39.96-
Total Non-Current Liabilities+33.91M19.66M28.13M44.7M248.32M591.42M739.08M822.5M805.97M437.25M
Long-Term Debt22.78M16.75M25.37M41.29M244.45M585.46M733.28M811.26M795.92M10.01M
Capital Lease Obligations2.7M2.75M2.7M3.41M3.87M5.96M5.8M11.23M10.05M0
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities244K155K54K000000427.23M
Total Liabilities88.27M94.49M97.61M137.03M353.98M695.14M844.6M972.49M966.35M633.31M
Total Debt+53.72M54.72M61.82M84.65M279.5M593.24M741.45M825.15M841.42M11.64M
Net Debt31.62M4.44M35.09M-29.52M7.38M88.85M436.69M714.5M736.5M-78.09M
Debt / Equity---2.21x------
Debt / EBITDA---------0.03x
Net Debt / EBITDA----------0.23x
Interest Coverage-7.49x-6.70x-10.27x-8.36x-12.05x-3.00x-1.50x-0.96x-0.03x-
Total Equity+-566.06M-631.84M-731.97M38.25M-19.26M-106.99M-294.6M-455.53M-475.93M-119.15M
Equity Growth %-10.79%-11.62%-15.85%105.23%-150.36%-455.43%-175.36%-54.63%-4.48%74.96%
Book Value per Share-7.68-7.48-7.090.33-0.12-0.60-1.58-2.37-2.30-0.55
Total Shareholders' Equity-566.06M-631.84M-731.97M38.25M-19.26M-106.99M-294.6M-455.53M-475.93M-119.15M
Common Stock738K984K1.1M1.54M1.77M1.84M1.88M2.06M2.08M2.13M
Retained Earnings-566.06M-631.84M-731.97M-840.63M-1.02B-1.21B-1.45B-1.68B-1.77B-1.51B
Treasury Stock0000000000
Accumulated OCI-12K-243K-297K39K3K177K26K1.34M921K38K
Minority Interest0000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-53.44M-41.14M-92.56M-89.58M-137.22M-142.16M-161.85M-95.14M-52.02M347.37M
Operating CF Margin %-202.78%-163.36%-448.19%-183.44%-770.36%-90.45%-59.76%-28.71%-11.54%39.71%
Operating CF Growth %-307.43%23.01%-124.98%3.22%-53.17%-3.6%-13.85%41.22%45.32%767.76%
Net Income-55.14M-65.78M-101.25M-108.9M-182.81M-184.06M-247.12M-226.54M-88.88M263.86M
Depreciation & Amortization483K704K770K724K748K777K1.44M1.66M1.25M1.39M
Stock-Based Compensation8.49M12.62M9.4M17.72M034.64M44.7M55.62M65.41M85.07M
Deferred Taxes-271K1.11M1.17M0000000
Other Non-Cash Items558K876K885K1.74M17.98M-1.64M98.07M106.53M57.48M-2.95M
Working Capital Changes-7.55M9.33M-3.53M-872K26.88M8.12M-58.95M-32.4M-87.28M0
Change in Receivables-2.52M2.65M568K-17.85M13.9M-20.82M-21.47M-6.09M-22.7M0
Change in Inventory1.11M500K-1.65M1.65M-7.04M-8.77M-12.42M-1.45M-4.16M985K
Change in Payables-10.52M3.84M4.49M11.74M17.36M39.41M-22.36M-16.81M-62.38M57.8M
Cash from Investing+23.34M-66.38M4.77M77.93M-6.86M15.8M-128.24M-131.5M52.59M-13.69M
Capital Expenditures-5.28M-328K-366K-343K-514K-2.38M-1.35M-2.17M-1.12M0
CapEx % of Revenue20.02%1.3%1.77%0.7%2.89%1.52%0.5%0.65%0.25%-
Acquisitions4K12K366K0000000
Investments----------
Other Investing66K-1.74M-366K01K0000-8.1M
Cash from Financing+23.3M135.7M62.5M99.1M302.7M359.67M88.03M32.48M-5.76M-349.93M
Debt Issued (Net)22.99M122K6.25M19.48M67.45M293.87M73.07M58.38M-1.7M0
Equity Issued (Net)01000K1000K1000K1000K1000K190K342K34K0
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing317K1.58M2.85M0124.71M15.73M14.77M-26.24M-4.09M-349.93M
Net Change in Cash-6.79M28.18M-25.29M87.45M158.63M233.39M-201.5M-193.79M-6.12M-14.99M
Free Cash Flow+-58.72M-41.47M-92.93M-89.93M-137.73M-144.54M-163.2M-97.31M-53.14M347.37M
FCF Margin %-222.8%-164.66%-449.96%-184.14%-773.24%-91.97%-60.26%-29.36%-11.79%39.71%
FCF Growth %-221.94%29.37%-124.09%3.23%-53.16%-4.95%-12.91%40.37%45.39%753.64%
FCF per Share-0.80-0.49-0.90-0.78-0.82-0.81-0.88-0.51-0.261.59
FCF Conversion (FCF/Net Income)0.97x0.63x0.91x0.82x0.75x0.77x0.65x0.42x0.59x1.32x
Interest Paid00000900K022.14M30.38M0
Taxes Paid00000118K3.54M1.43M1.6M0

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)----284.68%-1925.37%-----
Return on Invested Capital (ROIC)-------179.63%-38.79%-0.73%807.86%
Gross Margin89.76%93.24%97.72%91.6%90.59%95.38%97.57%98.59%97.23%97.82%
Net Margin-209.25%-261.18%-490.25%-222.99%-1026.35%-117.11%-91.25%-68.36%-19.72%30.16%
Debt / Equity---2.21x------
Interest Coverage-7.49x-6.70x-10.27x-8.36x-12.05x-3.00x-1.50x-0.96x-0.03x-
FCF Conversion0.97x0.63x0.91x0.82x0.75x0.77x0.65x0.42x0.59x1.32x
Revenue Growth-45.39%-4.43%-18%136.45%-63.53%782.38%72.31%22.37%36%94.1%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.